Reviewing PharmaCyte Biotech (OTCMKTS:PMCBD) and Tarsus Pharmaceuticals (NASDAQ:TARS)

PharmaCyte Biotech (OTCMKTS:PMCBD) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership.

Profitability

This table compares PharmaCyte Biotech and Tarsus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PharmaCyte Biotech	N/A	-49.09%	-43.39%
Tarsus Pharmaceuticals	-103.64%	-55.86%	-39.28%

Volatility & Risk

PharmaCyte Biotech has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of PharmaCyte Biotech shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares PharmaCyte Biotech and Tarsus Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PharmaCyte Biotech	N/A	N/A	-$3.83 million	N/A	N/A
Tarsus Pharmaceuticals	$182.95 million	9.75	-$135.89 million	($3.10)	-14.99

PharmaCyte Biotech has higher earnings, but lower revenue than Tarsus Pharmaceuticals.

Analyst Recommendations

This is a breakdown of current ratings and target prices for PharmaCyte Biotech and Tarsus Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PharmaCyte Biotech	0	0	0	0	0.00
Tarsus Pharmaceuticals	0	1	5	1	3.00

Tarsus Pharmaceuticals has a consensus target price of $63.67, indicating a potential upside of 37.01%. Given Tarsus Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than PharmaCyte Biotech.

Summary

Tarsus Pharmaceuticals beats PharmaCyte Biotech on 9 of the 12 factors compared between the two stocks.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.